Aerpio pharmaceuticals, inc. (ARPO)
Income statement / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10
License revenue, and other

-

20,157

-

-

-

-

-

-

-

-

Operating expenses
Research and development

12,824

17,852

12,147

11,367

11,625

-

-

-

-

-

Formation costs

-

-

-

-

-

0

0

0

0

0

General and administrative

9,756

13,485

9,241

5,265

5,861

23

22

22

23

20

Restructuring expense

1,863

-

-

-

-

-

-

-

-

-

Total operating expenses

24,444

31,338

21,388

16,633

17,486

-

-

-

-

-

Loss from operations

-24,444

-11,181

-21,388

-16,633

-17,486

-23

-22

-22

-23

-20

Grant income

142

6

93

131

369

-

-

-

-

-

Interest income

1,030

778

-105

-482

19

-

-

-

-

-

Other income, net

-

-

-

0

27

-

-

-

-

-

Total other income

1,173

784

-12

-349

416

-

-

-

-

-

Interest expense

-

-

-

-

-

6

5

4

3

1

Net and comprehensive loss

-23,270

-10,396

-21,400

-16,983

-17,070

-30

-28

-27

-27

-22

Net and comprehensive loss per share
Net and comprehensive loss

-23,270

-10,396

-21,400

-16,983

-17,070

-30

-28

-27

-27

-22

Extinguishment of preferred stock

-

-

-

224

-

-

-

-

-

-

Adjustment of redeemable convertible preferred stock to redemption value

-

-

943

4,152

348

-

-

-

-

-

Net loss attributable to common stockholders

-

-

-22,343

-20,912

-17,418

-

-

-

-

-

Basic and diluted

-0.57

-0.31

-1.03

-24.52

-31.14

-0.01

-0.01

-0.01

-0.01

0.00

Weighted average number of common shares used in computing net and comprehensive loss per share
Weighted average number of common shares used in computing net loss per share attributable to common stockholders, basic and diluted

40,588

33,930

21,673

852

559

5,000

5,000

5,000

5,000

-

Weighted-average number of common shares outstanding (in shares)

-

-

-

-

-

-

-

-

-

5,000